Emerging Therapeutic Options in Pancreatic Cancer Management

Int J Mol Sci. 2024 Feb 5;25(3):1929. doi: 10.3390/ijms25031929.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a 5-year survival rate of <8% [...].

Publication types

  • Editorial

MeSH terms

  • Carcinoma, Pancreatic Ductal* / drug therapy
  • Humans
  • Pancreatic Ducts / pathology
  • Pancreatic Neoplasms* / drug therapy
  • Survival Rate

Grants and funding

D.D.C. was supported by Fondazione Umberto Veronesi (FUV) and Fondazione Italiana per la ricerca sulle Malattie del Pancreas (FIMP).